NCT01496313 2025-10-03
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
Sanofi
Phase 4 Completed
Clinical Trials
40 trialsNCT00410761 2025-09-24
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
Sanofi
Phase 3 Completed
NCT01298323 2025-04-24
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
Sanofi
Phase 3 Completed
NCT04211337 2025-04-20
LIBRETTO-531
Eli Lilly and Company
Phase 3 Active not recruiting
NCT00537095 2024-04-19
Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer
Sanofi
Phase 2 Completed
NCT01586624 2021-10-07
A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)
Cancer Research UK
Phase 1 Completed
NCT03630120 2021-07-14
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT02495103 2021-01-26
Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01183559 2021-01-22
A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery
Fox Chase Cancer Center
Phase 1 Completed
NCT01414426 2021-01-14
Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions
University of Chicago
Phase 2 Completed
NCT00514046 2020-12-22
Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02015065 2020-03-30
Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00613626 2020-02-11
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT00459121 2019-03-26
Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT00441142 2019-03-05
Zactima
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT00923247 2018-11-29
A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00566995 2018-10-30
Phase II Study of Vandetanib in Individuals With Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00687297 2018-05-30
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
PrECOG, LLC.
Phase 2 Completed
NCT00098345 2018-05-07
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
Sanofi
Phase 2 Completed
NCT00364351 2018-01-25
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
Sanofi
Phase 3 Completed
NCT00500292 2018-01-25
A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer
Sanofi
Phase 2 Completed
NCT00358956 2017-01-30
A Study To Assess ZD6474 (ZACTIMAâ„¢) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
Sanofi
Phase 2 Completed
NCT00686036 2016-12-21
ZENITH
Sanofi
Phase 2 Terminated
NCT00872989 2016-12-19
S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00752986 2016-12-05
ZACFAST
Sanofi
Phase 2 Terminated
NCT01661179 2016-12-05
Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma
Sanofi
Phase 1/2 Completed
NCT00753714 2016-10-17
ZELIG
Sanofi
Phase 2 Completed
NCT00597116 2016-10-10
An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma
Sanofi
Phase 2 Terminated
NCT00753675 2016-10-10
VANGOGH
Sanofi
Phase 2 Completed
NCT00454116 2016-10-07
A Phase II, Double Blind Study of 2 Doses of ZACTIMAâ„¢(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients
Sanofi
Phase 2 Completed
NCT00498797 2016-10-07
E3-Hormone Refractory Prostrate Cancer Taxotere Combination
Sanofi
Phase 2 Completed
NCT00312377 2016-09-30
ZODIAC
Sanofi
Phase 3 Completed
NCT00404924 2016-09-30
ZD6474 (ZACTIMAâ„¢) Phase III Study in EGFR Failures
Sanofi
Phase 3 Completed
NCT00494481 2016-09-30
E3 Breast Cancer Taxotere Combination
Sanofi
Phase 2 Completed
NCT00290537 2016-05-19
Phase II Study of ZD6474 in Advanced NSCLC
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00995007 2016-03-29
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01372813 2015-10-23
Vandetanib to Treat Advanced Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00410189 2015-03-23
BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00459043 2013-07-03
Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00445549 2012-06-26
Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated